Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 6Recruiting 4Withdrawn 1Unknown 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 10Urinary Bladder Neoplasms 1Stomach Neoplasms 1Rectal Neoplasms 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1First-line Treatment 1Colorectal Cancer Metastatic 1Colonic Neoplasms 1Clinical Stage III Gastric Cancer AJCC v8 1

Interventions

Oxaliplatin 47Capecitabine 46Fluorouracil 40Leucovorin 30Radiotherapy 25Irinotecan 20Chemoradiotherapy 14Bevacizumab 14Cetuximab 12Neoadjuvant Therapy 11Folfox protocol 11Chemotherapy, Adjuvant 11XELOX 10Laparoscopy 10Drug Therapy 9Surgical Procedures, Operative 6Robotic Surgical Procedures 5Radiation 5Mastectomy, Segmental 5Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Panitumumab 4Gemcitabine 4FOLFOXIRI protocol 4durvalumab 3Simvastatin 3Magnetic Resonance Spectroscopy 3Indocyanine Green 3tislelizumab 2regorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Rectal Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03992456 2024-05-21

Panitumumab, Regorafenib, or TAS-102, in Treating Patients With Metastatic and/or Unresectable RAS Wild-Type Colorectal Cancer

Academic and Community Cancer Research United

Phase 2 Unknown
12 enrolled 16 charts
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡